Introduction {#Sec1}
============

The lysosomal storage disorder Gaucher disease (GD) results from a deficiency of the enzyme glucocerebrosidase (acid β-glucocerebrosidase, EC 3.2.1.45) which is involved in the breakdown of the glycosphingolipid glucocerebroside (Brady et al [@CR4]). In this autosomal recessively inherited disease, mutations in the gene encoding glucocerebrosidase (GBA1-gene) are the cause of deficient enzyme activity and result in accumulation of glucocerebroside in tissue macrophages. Major storage sites include spleen, liver, and bone marrow leading to a heterogeneous clinical picture with symptoms of hepatosplenomegaly, cytopenia, and bone disease. GD is phenotypically classified into three variants; type 1 is the most common, type 2 and 3 are the rare neuronopathic (acute and subacute respectively) forms (Grabowski [@CR17]). Therapy options include enzyme replacement therapy (ERT) and substrate reduction therapy, which have proven to be highly effective in reversing clinical signs and symptoms (Barton et al [@CR2]; Weinreb et al [@CR33]; Cox et al [@CR6]). Before the discovery of ERT, splenectomy was frequently performed in patients suffering from symptoms of severe splenomegaly. It has been hypothesized that after splenectomy patients are at an increased risk of liver complications, i.e., fibrosis and cirrhosis, and more extensive bone involvement (Fleshner et al [@CR15]; Lachmann et al [@CR21]; Bohte et al [@CR3]).

Over the years, it has become apparent that GD is associated with an increased risk of malignancies. In additoin to hematological malignancies, solid tumors in several organs have been described (Shiran et al [@CR30]; Zimran et al [@CR37]; de Fost et al [@CR7]; Taddei et al [@CR31]; Lo et al [@CR23]; Weinreb and Lee [@CR34]; Arends et al [@CR1]). A previously reported complication in GD is the occurrence of hepatocellular carcinoma (HCC) (Breiden-Langen et al [@CR5]; Erjavec et al [@CR13]; Xu et al [@CR36]).

HCC in the general population is mainly diagnosed in patients affected by a chronic liver disease, such as hepatitis B or C infection. The presence of cirrhosis is a main risk factor for the development of HCC (Forner et al [@CR16]; El-Serag [@CR11]). However, HCC can also occur in a non-cirrhotic liver (Schütte et al [@CR29]; Van Meer et al [@CR32]). Other risk factors include non-alcoholic fatty liver disease (NAFLD), hereditary haemochromatosis (HH) diabetes mellitus (DM), alcohol use, smoking, and obesity (Degasperi and Colombo [@CR8]; Kowdley [@CR20]; El-Serag et al [@CR12]; Marrero et al [@CR24]). Surveillance for HCC by biannual ultrasound examination is recommended for patients with a cirrhotic liver, irrespective of its etiology, and high-risk hepatitis B/C carriers (Diáz-González and Forner [@CR9]).

To date it is unknown which GD patients are especially at risk for developing HCC. Advanced liver involvement after splenectomy with subsequent fibrosis and cirrhosis, as stated above, has been suggested as a potential mechanism for the increased risk (de Fost et al [@CR7]). It is of interest to ascertain the factors, which contribute to the development of HCC in GD in order to be able to implement a rational screening protocol to detect these cancers at an early stage. With this international collaborative study we aim to summarize clinical and pathological findings of GD patients who developed a HCC in the past. We discuss the possible factors contributing to the development of this hepatic malignancy in relation to GD, compare our findings to existing literature on this topic and suggest a follow-up strategy for screening.

Methods {#Sec2}
=======

We retrospectively studied medical files of 16 type 1 GD patients with a confirmed HCC diagnosis from Gaucher referral clinics in the Netherlands, the United States of America, Germany, Italy, Israel, and France. Some of the cases have been previously described in the literature. All cases are described in terms of clinical, laboratory, and imaging findings. Parameters recorded for every patient include gender, age at GD diagnosis, genotype, spleen status, GD treatment, age at start of GD treatment, presence of bone disease, age at HCC diagnosis, laboratory findings at time of HCC diagnosis (iron status, alfa-foetoprotein, liver enzymes), known risk factors of HCC (hepatitis B/C, alcohol abuse, HFE-mutation, history of blood transfusions), imaging findings, therapy, complications, outcome, and pathology findings.

Results {#Sec3}
=======

Clinical data {#Sec4}
-------------

A summary of patient characteristics is shown in Table [1](#Tab1){ref-type="table"}. In all patients a diagnosis of Gaucher disease was confirmed based upon deficient activity of GBA and/or GBA1 mutation analysis. All patients had type 1 disease. A total number of 16 patients have been included, of whom ten patients (63%) were male. Eleven patients were splenectomized in the past. Mean age at which GD diagnosis was made was 26 years (range 3-60 years). The majority of patients (*n* = 14) were treated with ERT. The mean time between GD diagnosis and start of ERT was 20 years (range 0-41 years). Mean age at which HCC diagnosis was confirmed was 58 years (range 28-76 years). Therapeutic options for HCC, which have been applied in the studied cases include surgical resection (*n* = 6), liver transplantation (*n* = 2), percutaneous ablation (*n* = 3), transarterial chemoembolization (TACE; n = 6), immunotherapy (n = 1), chemotherapy (n = 1), radiotherapy (n = 1), and brachytherapy (n = 1) with some patients being treated with multiple treatment modalities. Three patients in this series are still alive after liver transplantation (case no. 12), resection of the liver tumor (case no. 14) or brachytherapy (case no. 16). All but one of the remaining 13 patients died as a consequence of the hepatocellular carcinoma or its complications. In one case (no. 5) another type of malignancy (gastro-esophageal, GE) was reported as final cause of death. This patient suffered from multiple malignancies beside the HCC and GE carcinoma.Table 1Characteristics of GD1 patients with a diagnosis of HCCNo.CountryGenderAge at GD diagnosisGenotypeSx (age at Sx)Bone diseaseGD therapy (age at start)Age at HCC diagnosisCourse and comorbidities or complicationsOutcome (age at death)1\*NLmale36N370S/I260TYes (53)yesAlglucerase (61)62Metastatic lesions peritoneum, omentumDied (63)2\*NLmale33N370S/N370SYes (33)yesAlglucerase, imiglucerase (44)63Resection of tumor, ablation, liver transplantation Recurrence of HCCDied (69)3\*NLfemale7N370S/L324PYes (13)yesAlglucerase, imiglucerase (37)55Resection of tumor, TACE-procedure Respiratory insufficiency, kidney failureDied (55)4\*NLfemale18R463C/?Yes (18)noAlglucerase, imiglucerase (34), miglustat39Vena porta thrombosisDied (39)5USAmale10N370S/L444PYes (36)yesAlglucerase, imiglucerase, velaglucerase (51)68Resection of tumor\
Multiple malignancies: bladder- and prostate carcinoma, gastro-oesophageal carcinomaDied (75)6GERmale50*Missing*NoyesImiglucerase (50)61TACE-procedure (3×)\
Recurrence of HCC, variceal bleedingDied (62)7GERfemale28N370S/?Yes (28)yesAlglucerase, imiglucerase, velaglucerase (51)68Resection of tumor, TACE-procedure\
Recurrence of HCC, metastatic bone lesionDied (71)8GERmale8*missing*Yes (8)noImiglucerase (8)\
eliglustat (trial)28Resection\
Recurrence of HCCDied (31)9ITmale41N370S/F213IYes (41)yesNot treated60Ablation (3×), TACE-procedure\
Recurrence of HCC, metastasisDied (65)10\*ISRfemale5N370S/84GGYes (16)yesAlglucerase (16)37Lung metastasis\
Ablation, xelodaDied (unknown)11ISRmale60N370S/N370SNonoNot treated*missing*Died (unknown12\*USAfemale3N370S/84GGYes (8)yesAlglucerase (37)47TACE, Liver transplantation, breast cancerAlive13FRmale57N370S/L324PNoyesImiglucerase, velaglucerase (74)76Venous thrombosis lower limbs, anemia, portal hypertension\
TACE-procedureDied (unknown)14FRfemale9N370S/ IVS2 G(+1)-TYes (18)yesAlglucerase, imiglucerase, velaglucerase (48)73Resection of tumorAlive15USAmale1884GG/1226GnoyesAlglucerase, imiglucerase (53)72SBRT, nivolomab, TACE\
Progressive HCC, no response to therapyDied (74)16GERmale37N370S/?noyesImiglucerase (37)58CBTAliveAbbreviations: NL, the Netherlands; USA, United States of America; GER, Germany; IT, Italy; ISR, Israel; FR, France. GD, Gaucher disease; HCC, hepatocellular carcinoma; Sx, splenectomy; TACE, transarterial chemo-embolisation; SBRT, stereotactic body radiotherapy; CBT, CT-guided brachytherapy\*Case previously described in literatureCases 1, 2 , 3, and 4 in Arends et al ([@CR1]), case 1 also in case report by Erjavec et al ([@CR13]), cases 1 and 4 in de Fost et al ([@CR7]), case 10 Zimran et al ([@CR37]), case 12 case report by Xu et al ([@CR36])

Laboratory findings and predisposing factors for HCC {#Sec5}
----------------------------------------------------

In Table [2](#Tab2){ref-type="table"} the laboratory data at time of HCC diagnosis is provided. Alfa-foetoprotein (αFP) levels show mild to extreme elevations in all but one case for whom data was available (*n* = 13). Information about hepatitis infection was available in 14 patients; this data was missing in two patients. Three of 14 patients were diagnosed with chronic hepatitis C infection (case no. 3, 9, and 10), and all showed elevated liver enzymes at time of HCC diagnosis. In nine hepatitis negative patients liver enzymes also showed mild elevations. Analysis of HFE-gene mutations was performed in six patients; one was homozygous for the C282Y mutation, one for C282Y/H63D mutations, and one heterozygous for H63D. A history of blood transfusion was recorded for six out of the nine patients for whom data was available. Ferritin levels were reported for 11 patients and increased in eight cases. Three out of eight patients, in whom transferrin saturation (Tsat) was analyzed, showed increased Tsat levels (\>45%). Iron overload in these cases was confirmed on histopathological examination. These patients are among the six patients with a known history of blood transfusions.Table 2Laboratory data and presence of predisposing factors for HCC of GD patients at time of HCC diagnosisNo.SxAFP (μg/L)ALAT (U/L)ASAT (U/L)AF (U/L)γGT (U/L)Albumin (g/L)Ferritin (μg/L)Transferrin saturation (%)Hepatitis B/C serologyHFE-mutationBlood transfusionAlcohol abuse\*Presence of fibrosis / cirrhosisIron staining1Yes83,6282361117974199531negative----No- / -Np2Yes18535386--38333465negativeH63D/wtYesNo+ / ++3Yes248689313718937375491Hep.C +wt/wtYesNo+ / ++4Yes16,281604163413722944115negative----NounknownNp5Yes10.524--------124--negative--NoNo- / ---6No6.47 (ref \<6.2 ng/ml)4643971544223--negative--YesNo+ / +Np7Yes26.1 ng/ml (ref \<8.116431206243----negative----No- / -Np8Yes41 ng/ml31359258448424negative----No+ / +Np9Yes44.6916921110644447046Hep. C+Wt/wtYes--- / -+10Yes29,2523843559312282.5?----Hep. C+--Yes--? / +Np11No--162016214.3?31----C282Y/C282Y----unknownNp12Yes1614710218978624----Hep. B +----No+ / +Np13No--105802044404146325NegativeC282Y/H63DYes--? / +Np14Yes--1625873340389--Negative--No--? / +Np15No683847682--3510597NegativeWt/wtNoNo- / - \*\*--16No643296821741----------No? / +NpAbbreviations: Np, not performed; Sx, splenectomy\*Alcohol abuse is defined as prolonged intake of 40-60 g of alcohol/day (standard drink containing 13.7 g) (El-Serag [@CR11]) or a known history of alcohol abuse\*\*Histopathological examination only revealed tumorous tissue, no normal liver tissue. Although not confirmed, the presence of cirrhosis in this case is suspected

Histopathological findings {#Sec6}
--------------------------

Pathology information was available for 14 cases (see Table [2](#Tab2){ref-type="table"}). In nine cases the presence of liver cirrhosis was reported. In one case (no.15) only tumorous tissue was found on histopathological examination. The presence of cirrhosis in surrounding liver tissue is suspected but not confirmed. The remaining four patients did not show evidence for fibrosis or cirrhosis. Iron staining of liver tissue was described in five cases, of which three were found positive (case no. 2, 3, and 9). Iron loading was present in macrophages as well as in hepatocytes up to grade 3. In these three cases, Tsat-values all exceed 45% as described in the previous paragraph. Cases 2 and 3 were also found to have a cirrhotic liver, whereas case no. 9 did not show evidence of fibrosis or cirrhosis. An example of histological findings is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Histology findings of liver tissue of case no. 2**a** Clear demarquation of HCC lesion and liver parenchyma (arrow); **b** Higher magnification with clear atypia and solitary artery (arrow); **c** Prussian blue staining, indicating the presence of iron in hepatocytes and Kupffer cells in blue; **d** Surrounding liver characterized by cirrhosis with nodular architecture and presence of fibrous bands (red). There is also the component of steatosis (arrow)

Imaging findings {#Sec7}
----------------

Data on imaging findings is missing in three cases. In the remaining 13 cases imaging characteristics of the lesions have been described in ultrasound (US) in five cases, magnetic resonance imaging (MRI) in six cases, and computed tomography (CT) in 11 cases. The characteristics of the carcinomas appearing on the available imaging modalities vary. In five cases in which contrast imaging was performed, all lesions showed arterial enhancement. In three of these cases the typical wash-out of contrast agent was also described. The presence of multiple malignant lesions in the liver, i.e., multifocal hepatocellular carcinoma, has been described in nine cases. An additional imaging modality used to assess the degree of liver stiffness is transient elastography (TE; Fibroscan©). In three patients (case no. 2, 6, and 7) this method was used, and in all three patients increased liver stiffness values were reported, suggesting the presence of liver fibrosis. Based on validation in non-GD patients and observation in a small cohort of GD (Guo et al [@CR18], Bohte et al [@CR3]), it is likely that elastography in GD represents fibrotic changes, although lysosomal accumulation by itself could contribute to this.

Discussion {#Sec8}
==========

This study describes a worldwide case series of 16 GD patients who were diagnosed with HCC. Two patients in this study have been described in detail previously (case no. 1 (Erjavec et al [@CR13]) and case no. 12 (Xu et al [@CR36]). Two other cases of HCC reported in the literature were found that have not been included in this series. In 1982, Lee described a 67-year old GD patient who died from HCC (Lee [@CR22]) and another case report was published in which a 48-year old GD patient with HCC in a cirrhotic liver was discussed. This patient also suffered from hepatitis B (Breiden-Langen et al [@CR5]). All cases previously published, were GD patients who had undergone splenectomy in the past. A summary of published cases was provided by Arends et al ([@CR1]) and six of the cases described were also included in this series.

In our current study, we have shown that HCC also occurs in GD patients with an intact spleen (*n* = 5). Liver cirrhosis or fibrosis was present in nine patients. Of importance, four cases were described in which HCC developed in a non-cirrhotic liver. One patient (no. 15) had no pathologically confirmed cirrhosis (biopsy retrieved only malignant tissue and no surrounding nonmalignant tissue) but had presented 20 years before the HCC diagnosis with liver failure and had been assumed by his physician to have had cirrhosis. Three patients were shown to have iron overload in the liver, one of those (no. 9) did not show any sign of fibrosis or cirrhosis, whereas the other two iron-overloaded cases had concomitant cirrhosis. The concurrence of a previous hepatitis B infection in one patient and chronic hepatitis C in three other cases points to this as another important risk factor for HCC. In one case the presence of homozygosity for the C282Y mutation in the HFE-gene indicates that this patient possibly suffers from hereditary haemochromatosis as well as GD. However, detailed information regarding this case was missing.

In a liver affected by GD, replacement of normal liver tissue by pathological storage cells can induce the development of a spectrum of abnormalities (James et al [@CR19]). In the pre-ERT era, splenectomy was frequently performed in GD patients. It is thought that after removal of the spleen, advanced hepatic involvement in the GD storage process is a main risk factor for liver-related complications (de Fost et al [@CR7]). It has been shown that splenectomized GD patients do show significantly higher liver stiffness values as compared to GD patients with an intact spleen (Bohte et al [@CR3]). The risk of liver-related complications in this population is associated with the presence of liver fibrosis (James et al [@CR19]; Lachmann et al [@CR21]). In addition, it should be noted that a population of Gaucher cells associated with fibrous septa in the liver does not disappear in response to ERT, indicating the presence of residual storage which is insensitive to the administered enzyme (Lachmann et al [@CR21]; Perel et al [@CR27]).

The mechanisms responsible for the increased risk for malignancies in GD are not fully understood and several factors have been implicated to play a role. The main factors related to the primary genetic defect in GD include immune dysregulation, chronic macrophage activation inducing elevated release of several pro- and anti-inflammatory cytokines, cellular dysfunction due to the accumulation of glucocerebroside and glucosylsphingosine (Arends et al [@CR1]; Mistry et al [@CR25]). The etiology of hepatic carcinogenesis in GD patients is likely to be a result of the abovementioned factors together with the presence of other, HCC-specific, risk-factors and coexistent conditions.

In 80-90% of the patients with HCC worldwide, liver cirrhosis is the underlying cause (Fattovich et al [@CR14]). In nine cases in the current study, the presence of fibrosis and/or cirrhosis was confirmed; in one it was highly suspected. Advanced hepatic involvement of GD after splenectomy could explain the progression of liver disease. However, three patients had an intact spleen but did develop liver cirrhosis. One of those (no. 13) was recorded to have the C282Y/H63D mutation of the HFE-gene, indicating that iron overload as a consequence of hereditary hemochromatosis might contribute to the development of HCC. Two others with intact spleen and liver cirrhosis (case no. 6 and 16) were not reported to have any clear other risk factors, although some data is missing regarding these cases. As liver fibrosis is the preceding histological hallmark of liver cirrhosis, detecting fibrosis is an important step in defining patients at risk for cirrhosis and subsequent HCC development in GD.

An important finding of the current study is that in four GD patients HCC developed in a liver with no signs of fibrosis or cirrhosis (no. 1, 5, 7, and 9). All were splenectomized in the past. The time in between GD diagnosis and start of ERT treatment is 25, 41, and 23 years for cases 1, 5, and 7 respectively. This long untreated state of those patients could potentially contribute to the increasing pathological Gaucher cell burden and subsequent general risk of malignancy. Case 9 was not treated with ERT. Aside from GD, he also suffered from hepatitis C and did develop severe iron overload. Taken together, these factors could all contribute to the occurrence of HCC. Three of four non-cirrhotic GD patients who developed HCC were treated with alglucerase in the past. Alglucerase was the first macrophage-targeted enzyme preparation available (Barton et al [@CR2]). This enzyme preparation was produced by purifying glucocerebrosidase from human placental tissue, and as a consequence, contains human choriogonadotropin (hCG). HCG can be produced by liver tumors, and as such, hCG may have been contributory to the development of HCC (Erjavec et al [@CR13]; Nakanuma et al [@CR26]).

Extremely elevated serum ferritin levels in GD patients despite adequate treatment with ERT or SRT are associated with increased iron storage (Regenboog et al [@CR28]). This finding is confirmed in the current study, in which three patients with serum ferritin levels exceeding 3000 μg/l and Tsat \>45% did show evidence of iron loading on histology examination of liver tissue. When available, quantitative magnetic resonance imaging (MRI) of iron might serve as an additional tool in diagnosing and monitoring iron overload (Wood [@CR35]). MRI iron measurements were not available for the cases described. GD itself could be the explanation for a distorted iron metabolism. However, the co-existence of pathological mutations in the HFE-gene should not be missed. As hepatic iron overload can cause toxicity and is associated with carcinogenesis (Kowdley [@CR20]), it is considered a potential contributing factor to the HCC-risk in GD patients.

A limitation of the current study is the fact that for some investigated risk factors, data were not complete. In addition, risk factors for HCC development in general, for example smoking status, the presence of diabetes mellitus or obesity were not recorded for most patients and therefore not included. Indeed, metabolic syndrome is probably more frequent in GD. However, in the Dutch cohort, none of the patients who developed HCC had signs of metabolic syndrome. This does not exclude the possibility that these factors could have contributed to the malignant transformation of liver tissue in our studied cohort.

In current practice, we strongly advise careful surveillance of GD patients at risk for HCC. Early detection of possible malignant lesions might prevent HCC-related mortality in this population. It is important to define the GD patients who are at risk for HCC. Given the importance of fibrosis in identifying patients at risk for HCC, practical recommendation could be to investigate all GD patients for the presence of liver fibrosis by transient elastography (TE; Fibroscan ©). Based on clinical expertise, literature, and the current case series subsequent close follow-up for the development of HCC would be limited to those GD patients for whom 1 or more of the following risk factors is present:Splenectomized patientsPresence of liver fibrosis/cirrhosisPersistent hyperferritinemia (\> 2 times upper limit of normal) despite adequate GD-specific treatment in combination with transferrin saturation \> 45%Chronic hepatitis B/C carriers

According to the guidelines for HCC-surveillance of the European Association for the Study of the Liver, a 6-month interval for surveillance is preferable (*EASL-EORTC clinical practice guidelines*[@CR10]). First-choice testing for HCC surveillance is ultrasound (US) examination. The use of alpha-foetoprotein (AFP) as a serological marker for HCC together with US is not recommended. Since the incidence of HCC is probably very low, and in Western Countries with effective treatment available perhaps even lower, a review of prospectively detected cases by screening should be performed to evaluate the (cost-) effectiveness of the proposed strategy.

In summary, HCC in GD patients is shown to occur in non-cirrhotic as well as cirrhotic livers, irrespective of splenectomy status, although splenectomy itself seems to be a risk factor for fibrosis/cirrhosis. Other contributing factors, such as iron overload and the presence of hepatitis, have been detected. This cohort of patients is characterized by the presence of severe and longstanding disease. It should be clear that most of the patients are diagnosed with GD prior to the discovery and implementation of ERT. The future will show whether timely diagnosis and start of therapy for GD also decreases the risk of malignancies.
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